DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Menu 返回 Pharmacovigilance

Pharmacovigilance and Safety

Overview of the global regulatory environment for clinical safety and pharmacovigilance for medical products (biopharmaceutical products, advanced therapies and medical devices).

The focus is on pragmatic approaches for ensuring patient safety and ensuring that the patient voice is properly heard in the complex and evolving pharmacovigilance ecosystem. The forward-thinking sessions will address how to apply new technologies and methods for streamlining pharmacovigilance systems and processes. This will help enhance patient safety as products become progressively more complex, new data sources drive new analytical techniques, regulatory requirements.

Who is This Track Designed For?

Professionals involved in drug safety/pharmacovigilance, medical product safety risk assessment, pharmacoepidemiology (including real-world evidence generation), post-marketing studies (including Large Simple Trials and pragmatic safety studies), statistics, benefit-risk assessment and management, benefit-risk communication (including professional and consumer medical product safety labelling), regulatory affairs, clinical research (including clinical trial design), medical affairs and health outcomes.

Register Now

DIA Europe 2022 Brochure

The online program is now available. Explore the rich content we offer across 10 thought leadership tracks. 

View Searchable Programme

Topic Leaders

Álmath Máire Spooner

Álmath Máire Spooner, PhD, RPh

Director of Regulatory Policy and Intelligence

AbbVie, Ireland

Raphael Van Eemeren

Raphael Van Eemeren

EU QPPV Director, Global Patient Safety

Amgen AB, Sweden

DIA Europe 2022 Highlights

It will provide updates on key developments on the GCP Renovation (ICH E6, ICH E8), Clinical Trial Regulation, the Clinical Trial Information System, data submission, transparency, navigating ethical approval, study design in the digital age, innovative clinical trial designs (umbrella and platform trials, patient centricity), digital tools in development and other hot topics. It should be a must-attend for optimising development programmes and identifying cost savings through efficiency and innovation.


Explore All Tracks

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。